ArticleFrontiers in pharmacology2025
Case Report: Hydronephrosis and nephrogenic adenoma secondary to Stevens-Johnson syndrome.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stevens-Johnson syndrome is a rare, severe cutaneous adverse reaction. There is a lack of literature reporting the complications of the bladder and ureter caused by Stevens-Johnson syndrome. In this case, we describe a 10-year-old boy with hydronephrosis and nephrogenic adenoma secondary to Stevens-Johnson syndrome. Case description: A boy was admitted to our hospital after a CT scan revealed bilateral hydronephrosis. He had been diagnosed with Stevens-Johnson syndrome earlier. Ureteroscopy and bilateral retrograde ureteral stenting were performed. After the guidewires were introduced, a mass of mucosal debris gushed from the ureteral orifices. Biopsy findings of the mucosal lesions were consistent with nephrogenic adenoma. Two months later, ultrasonography revealed worsening hydronephrosis. The double-J stents were removed. Follow-up ultrasonography showed an improvement in the hydronephrosis. Conclusion: Stevens-Johnson syndrome is a life-threatening mucocutaneous disorder. Ureteral obstruction and hydronephrosis can be caused by mucosal debris in patients with Stevens-Johnson syndrome, which may contribute to and exacerbate renal dysfunction. Nephrogenic adenoma can occur to patient with Stevens-Johnson syndrome as a result of the proliferation of implanted renal tubular cells. Routine ultrasonography should be conducted to monitor the urinary system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.